ABSTRACT
Extracting population-wise information from medical images, specifically in the neurological domain, is crucial to better understanding disease processes and progression. This is frequently done in a whole-brain voxel-wise manner, in which a population of patients and healthy controls are registered to a common co-ordinate space and a statistical test is performed on the distribution of image intensities for each location. Although this method has yielded a number of scientific insights, it is further from clinical applicability as the differences are often small and altogether do not permit for a performant classifier. In this paper, we take the opposite approach of using a performant classifier, specifically a traditional convolutional neural network, and then extracting insights from it which can be applied in a population-wise manner, a method we call voxel-based diktiometry. We have applied this method to diffusion tensor imaging (DTI) analysis for Parkinson’s Disease, using the Parkinson’s Progression Markers Initiative (PPMI) database. By using the network sensitivity information, we can decompose what elements of the DTI contribute the most to the network’s performance, drawing conclusions about diffusion biomarkers for Parkinson’s disease that are based on metrics which are not readily expressed in the voxel-wise approach.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Institut des Neurosciences Cliniques de Rennes and SAD Region Bretagne.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All data was from the Parkinson's Progression Markers Initiative (PPMI) from the Michael J. Fox Foundation.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
A. Estudillo Romero (alfonso.estudillo{at}univ-rennes1.fr)
C. Haegelen (now with CHU de Lyon) (claire.haegelen{at}chu-lyon.fr)
P. Jannin (pierre.jannin{at}univ-rennes1.fr)
Data Availability
All data was from the Parkinson's Progression Markers Initiative (PPMI) from the Michael J. Fox Foundation.
